HS-20093 drug page Clinical trials

Trials with HS-20093

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

3Trials
2Recruiting
1Countries
1.479Planned patients

Showing 1–3 of 3

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Recruiting Phase 1 157 patients NCT06769425

HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.

China May 2025 – Aug 2026 Interventional
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Recruiting Phase 1 560 patients NCT06825624

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics …

China Oct 2024 – Dec 2026 Interventional
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Not yet recruiting Phase 1 762 patients NCT06963502

This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced or metast…

China May 2025 – Apr 2030 Interventional

Where the recruiting trials are